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There is established concept that dendritic cells (DCs) play essential roles in the development of allergic immune responses.
However,theinﬂuenceofH1 receptorantagonistsonDCfunctionsisnotwelldeﬁned.Theaimofthepresentstudywastoexamine
the eﬀect of epinastine hydrochloride (EP), the most notable histamine H1 receptor antagonists in Japan, on Dermatophagoides
farinae (Der f)-pulsed mouse bone marrow-derived DCs in vitro and in vivo. EP at more than 25ng/mL could signiﬁcantly inhibit
the production of IL-6, TNF-α and IL-10 from Der f-pulsed DCs, which was increased by Der f challenge in vitro. On the other
hand, EP increased the ability of Der f-pulsed DCs to produce IL-12. Intranasal instillation of Der f-pulsed DCs resulted in nasal
eosinophiliaassociatedwithasigniﬁcantincreaseinIL-5levelsinnasallavageﬂuids.Derf-pulsedandEP-treatedDCssigniﬁcantly
inhibited nasal eosinophila and reduced IL-5. These results indicate that EP inhibits the development of Th2 immune responses
through the modulation of DC functions and results in favorable modiﬁcation of clinical status of allergic diseases.
Copyright © 2009 Ken-Zaburo Oshima et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Allergic rhinitis is an inﬂammation of the nasal passages,
usually associated with watery nasal discharge, sneezing
and itching of the nose. These clinical symptoms are also
well accepted to be mediated by vasoactive substances,
arachidonic acid metabolites, cytokines and chemokines
secreted from inﬂammatory cells, including eosinophils,
mast cells, and T cells [1]. The initial response in the
development of allergic inﬂammation is an allergen, such
as mite and pollen, being presented to the nasal mucosa.
This allergen is then recognized as an antigen by antigen-
presenting cells (APCs) and presented to plasma cells. These
cells subsequently produce IgE and attach themselves to
mast cells and eosinophils awaiting re-exposure. Upon re-
exposure, an antigen-antibody complex is formed and acti-
vate inﬂammatory cells to secrete several factors responsible
for allergic immune responses [2].
The goal of management of allergic immune responses,
including allergic rhinitis is to reduce the clinical symptoms
caused by the inﬂammation of aﬀected tissues. Avoidance
of the allergens or minimization of contact with them is
the best treatment, but some relief may be found with the
pharmacological medications. Pharmacotherapy available
for allergic rhinitis is vast. Although several studies have
demonstrated that corticosteroids are the most eﬀective
agents in the treatment of allergic airway diseases, including
allergic rhinitis, the use of this class of drugs may be
limited because of concerns over unwanted side eﬀects [3].
In contrast, antihistamines are commonly used as the ﬁrst-
line treatment for allergic rhinitis and successful results are
reported [3–5]. Although primal target of antihistamines
is the histamine H1 receptor, these drugs act as inhibitors
of the synthesis and release of chemical mediators and
inﬂammatory cytokines from eosinophils and mast cells2 Mediators of Inﬂammation
following immunological and nonimmunological stimula-
tions [6, 7]. Antihistamines also reported to be able to
suppress the ability of leukocytes to produce inﬂammatory
cytokines and chemokines in response to inﬂammatory
stimulations [8, 9]. Furthermore, our previous works clearly
showed the suppressive activity of antihistamines, especially
fexofenadine hydrochloride, on nasal ﬁbroblasts to produce
inﬂammatory mediators, such as nitric oxide and matrix
metalloproteinases induced by inﬂammatory stimulation
[10, 11]. These reports strongly suggest that antihistamines
modulate the function of cells, which are responsible for
the development of allergic inﬂammation, and results in
favorable modiﬁcation of the allergic disease state or con-
ditions. On the other hand, there is established concept
that dendritic cells (DCs), the most potent APC in airways,
play essential roles in the development of allergic immune
responses through the production of immunomodulatory
cytokinesandexpressionofcostimulatorymoleculesontheir
cell surface [12–14]. A number of studies reported the eﬀects
of several types of agents, cysteinyl leukotriens receptor
antagonists[13,15],β2-adrenargicreceptorantagonists[16],
andcorticosteroids[13,16],whichareusedforthetreatment
of airway inﬂammatory diseases, on DC functions, while a
few examined the eﬀects of antihistamines on DCs.
In the present study, we examined the inﬂuence of
epinastine hydrochloride (EP), the most notable H1 receptor
antagonist in Japan, on the functions of DCs using mite
allergen-pulsed murine bone marrow-derived DCs in vitro
and in vivo.
2.MaterialsandMethods
2.1. Mice. Speciﬁc pathogen-free female BALB/c mice, 7
weeks old, were purchased from Charles River Japan Inc.,
(Kanagawa, Japan) and maintained in our animal facilities
at 25±2◦C, 55±5% humidity and 12-hour light/dark cycle.
Each experimental and control group consisted of ﬁve mice.
All animal experimental procedures were approved by the
Animal Care and Use Committee of Showa University.
2.2. Reagents. EP was kindly donated from Nippon
Boehringer Ingelheim Co., Ltd. (Tokyo, Japan) as a
preservative-free pure powder. EP was dissolved in RPMI-
1640 medium (Sigma Aldrich, Mo, USA) supplemented
with 10% heat-inactivated fetal calf serum (RPMI-FCS)
at a concentration of 1.0mg/mL, sterilized by passing
through a 0.2μmﬁ l t e ra n ds t o r e da sas t o c ks o l u t i o na t4 ◦C
until used. Mite extract Dermatophagoides farinae (Der f)
was obtained from Cosmo Bio Co., Ltd. (Tokyo, Japan).
Contamination of lipopolysaccharide (LPS) in the Der f
preparations was <0.96EU/mg Der f as assessed by Limulus
amebocyte lysate test (Sigma Aldrich). Recombinant mouse
granulocyte/macrophage colony stimulating factor (rmGM-
CSF), preservative free, was purchased from R&D Systems
Inc. (Minn, USA).
2.3. Induction of DCs. Murine bone marrow-derived DCs
were induced as described previously [17]. Brieﬂy, femurs
and tibiae of BALB/c mice (10 mice) were removed and puri-
ﬁed the surrounding muscle tissue. Both ends were cut and
the marrow ﬂushed with phosphate-buﬀered saline (PBS).
After washing ﬁve times with PBS containing 500U/mL
penicillin, 500μg/mL streptomycin, and 10μg/mL ampho-
tericin B, bone marrow cells were suspended in RPMI-
FCS at a concentration of 2 × 106 cells/mL and cultured
in 100mm culture plates in a ﬁnal volume of 10.0mL. At
day 3, another 10.0mL of RPMI-FCS containing 20.0ng/mL
rmGM-CSF was added to the plates. On day 6, half of the
culture medium was changed with fresh medium containing
5.0ng/mL rmGM-CSF.
2.4. Preparation of Antigen-Pulsed and EP-Treated DC. DCs
w e r ec o l l e c t e do nd a y8 ,w a s h e do n c ew i t hR P M I - F C S ,
resuspended at 2×106 cells/mL in RPMI-FCS that contained
5.0ng/mLrmGM-CSF.Thesecellswerethenintroducedinto
24-well culture plates in triplicate that contained various
concentrations (0, 20, 25, 30, and 35ng/mL) of EP in a ﬁnal
volume of 2.0mL. After 2 hour, Der f was added to cell
cultures to give a ﬁnal concentration of 100μg/mL. Cell-
free culture supernatants collected after 24-hour incubation
were stored at −80
◦C until used. To prepare Der f-pulsed
a n dE P - t r e a t e dD C sf o ri nv i v ou s e ,D C sc o l l e c t e do nd a y
8 were cultured with 25.0ng/mL EP in a ﬁnal volume of
10.0mL. After 2 hours, 100μg/mL Der f was added to cell
cultures, and incubated for a further 24 hours. The cells were
then collected, washed three times, and resuspended in PBS
at concentration of 2 × 107 cells/mL and used for in vivo
experiments.
2.5. Immunization with Der f-Pulsed DCs and Exposure to
Allergen In Vivo. Na¨ ıve BALB/c mice were lightly anes-
thetized with ether and divided into six groups (ﬁve
mice/group).Topreparenon-DCinstilledcontrol,micewere
received intranasally with 50μgo fDer f once daily for 5
consecutive days in a volume of 50μL. Der f nonpulsed
control DCs and Der f-pulsed DCs (1 × 106 cells/50μL) was
applied at the tip of the nose with a micropipet and inhaled
involuntarily [15, 16, 18]. These mice were then challenged
intranasally with either PBS or 50μgo fDer f (50μL, each)
once daily for 5 consecutive days, which was started 10 days
after cell instillation. The remaining one group of mice were
intranasally instilled with Der f-pulsed DCs pretreated with
25ng/mL EP and challenged with Der f in a similar manner.
2.6. Preparation of Nasal Cavity Lavage Fluid (NLF). Mice
were killed by intraperitoneal injection with 1.0mL of
50mg/mL sodium pentobarbital (Abbott Laboratories, Ill,
USA) 24 hours after ﬁnal Der f challenge [15, 16], and
a midline incision was performed above the sternum. The
trachea was exposed by blunt dissection and a 28 gauge
plastic tube was inserted into trachea above the carina
to nasal cavity. The both sides of nasal cavity were then
simultaneously lavaged with 1.0mL PBS. Aliquots of the
nasal lavage ﬂuid were then centrifuged at 3000g at 4◦Cf o r
15 minutes, and the supernatants were collected and storedMediators of Inﬂammation 3
Med.
alone
02 02 53 03 5
Der f+EP(ng/ml)
0
500
1000
1500
2000
2500
F
a
c
t
o
r
l
e
v
e
l
s
(
m
e
a
n
p
g
/
m
l
±
S
E
)
IL-10 P>. 05 P<. 05 P<. 05
Med.
alone
02 02 5 3 03 5
Der f+EP(ng/ml)
0
500
1000
1500
2000
2500
3000
F
a
c
t
o
r
l
e
v
e
l
s
(
m
e
a
n
p
g
/
m
l
±
S
E
)
IL-12p40
P>. 05 P<. 05
Figure 1: Inﬂuence of epinastine hydrochloride (EP) on immunomodulatory cytokine production from dendritic cells (DCs) stimulated
withDermatophagoidesfarinae(Derf) in vitro. DCs derived from bone marrow of BALB/c mice were stimulated with Derf inthepresenceof
various concentrations of EP for 24 hours. IL-10 and IL12p40 levels in culture supernatants were examined by ELISA. The data are expressed
as the mean pg/mL ± SE of triplicate cultures. This is one of two diﬀerent experiments, which gave reproducible results.
at −80
◦C until use. The pellets spended in 1mL PBS were
used for counting eosinophils and lymphocytes.
2.7. Assay for Cytokines. Concentrations of immunomodu-
latory cytokines, IL-12p40 and IL-10, and proinﬂammatory
cytokines, IL-6 and TNF-α in DCs culture supernatants
were measured using commercially available mouse cytokine
ELISA assay kits (R&D Systems Inc.) according to the
manufacturer’s instructions. IL-5 and IFN-γ in NLF were
also assayed by mouse cytokine ELISA assay kits (Pierce
Biotechnology Inc., Ill, USA). The detectable minimum
levels of these ELISA kits were 15pg/mL for IL-12p40,
15.0pg/mLforIL-10,3.0pg/mLforIL-6,3.0pg/mLforTNF-
α, 5.0pg/mL for IL-5, 10.0pg/mL for IFN-γ,r e s p e c t i v e l y .
2.8. Counting for Lymphocytes and Eosinophils in NLF. Total
number of lymphocytes in NLF were counted with Turk’s
solution and hemocytometers. The number of eosinophils
in NLF was examined using Hinkelman’s solution and
hemocytometers.
2.9. Statistical Analysis. Statistical diﬀerence were examined
using analysis of variance (ANOVA), followed by Fisher’s
PLSD test. A P-value less than .05 denoted the presence of
a statistically signiﬁcant diﬀerence.
3. Results
3.1. Inﬂuence of EP on Cytokine Production from DCs In
Vitro. The ﬁrst experiments were undertaken to examine
the inﬂuence of EP on cytokine production from DCs after
Der f stimulation in vitro. As shown in Figure 1,D C sc o u l d
produce much higher (P<. 05) levels of IL-10 in response
to Der f stimulation as compared with nonstimulated DCs.
On the other hand, addition of EP into cell cultures dose
dependently suppressed the ability of DCs to produce IL-10
(Figure 1). The minimum concentration of EP that caused
signiﬁcant suppression was 25ng/mL (Figure 1). In contrast
to the case of IL-10, IL-12p40 levels in culture supernatants
was further increased by the treatment of DCs with EP,
when EP at more that 25ng/mL was added to cell cultures
(Figure 1). We then examined the inﬂuence of EP on the
production of IL-6 and TNF-α f r o mD C si nr e s p o n s et o
Der f stimulation. As shown in Figure 2,t r e a t m e n to fD C s
with EP at more than 25ng/mL signiﬁcantly suppressed the
production of IL-6 and TNF-α, which were increased by Der
f stimulation in vitro.
3.2. Inﬂuence of Intranasal Instillation of DCs on the Appear-
ance of Inﬂammatory Cells in NLF. The second experiments
were designed to examine the inﬂuence of intranasal instilla-
tionofDCsoninﬂammatorycellappearanceinnasalwall.As
shown in Figure 3, intranasal instillation of Der f, nonpulsed
DCs, nonpulsed DCs and challenged Der f, and pulsed DCs
could not cause the apparent changes in inﬂammatory cell
appearance in nasal wall: NLF obtained from these groups
of mice contained similar numbers (not signiﬁcant; P<
.05) of both eosinophils and lymphocytes. On the other
hand, NLF obtained from mice instilled with Der f-pulsed,
nontreated DCs and challenged with Der f contained higher4 Mediators of Inﬂammation
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Figure 2: Inﬂuence of epinastine hydrochloride (EP) on proinﬂammatory cytokine production from dendritic cells (DCs) stimulated with
Dermatophagoides farinae (Der f) in vitro. DCs derived from bone marrow of BALB/c mice were stimulated with Der f in the presence of
various concentrations of EP for 24 hours. IL-6 and TNF-α levels in culture supernatants were examined by ELISA. The data are expressed
as the mean pg/mL ± SE of triplicate cultures. This is one of two diﬀerent experiments, which gave reproducible results.
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Figure 3: Inﬂuence of nasal antigenic challenge on inﬂammatory cell appearance in nasal lavage ﬂuid obtained from mice instilled nasally
withDermatophagoides farinae (Der f)-pulsed dendritic cells. BALB/c mice were instilled nasally with Der f-pulsed and 25ng/mL epinastine
hydrochloride (EP)-treated DCs. Nasal lavage was performed 24 hours after the ﬁnal Der f allergen exposure. The data are expressed as the
mean number of cells ± SE of ﬁve mice. This is one of two diﬀerent experiments, which gave reproducible results. Der f alone: Der f allergen
exposure alone; N.DC alone: nonpulsed DC instilled; N.DC + Der f: nonpulsed DC instilled and Der f allergen exposure; P. DC alone: Der
f-pulsed DC instilled; P. DC + Der f: Der f-pulsed DC and Der f a l l e r g e ne x p o s u r e ;P .D C+Der f +E P :Der f-pulsed, EP-treated DC and
Der f exposure.Mediators of Inﬂammation 5
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Figure 4: Inﬂuence of nasal antigenic challenge on inﬂammatory cytokine appearance in nasal lavage ﬂuid obtained from mice instilled
nasally with Dermatophagoides farinae (Der f)-pulsed dendritic cells. BALB/c mice were instilled nasally with Der f-pulsed and 25ng/mL
epinastine hydrochloride (EP)-treated DCs. Nasal lavage was performed 24 hours after the ﬁnal Der f allergen exposure. The data are
expressed as the mean pg/mL ± SE of ﬁve mice. This is one of two diﬀerent experiments, which gave reproducible results. Der f alone: Der
f allergen exposure alone; N. DC alone: nonpulsed DC instilled; N. DC + Der f: nonpulsed DC instilled and Der f a l l e r g e ne x p o s u r e ;P .D C
alone: Der f-pulsed DC instilled; P. DC + Der f: Der f-pulsed DC and Der f a l l e r g e ne x p o s u r e ;P .D C+Der f +E P :Der f-pulsed, EP-treated
DC and Der f e x p o s u r e .N .D . :n o td e t e c t e d .
numbers (P<. 05) of both eosinophils and lymphocytes as
compared with control mice. The data in Figure 3alsoclearly
indicatesthattreatmentofDerf-pulsedDCswithEPinvitro
prevented signiﬁcantly (P<. 05) increase in eosinophils and
lymphocytes in NLF induced by Der f intranasal challenge.
3.3. Inﬂuence of EP on Cytokine Production from DCs In Vivo.
The third experiments were carried out to examine whether
in vitro changes in the ability of DCs to produce cytokines
was also observed in vivo. NLF obtained from mice instilled
nonpulsed DCs contained much lower levels of IL-5, even
when these mice were challenged intranasally with Der f
(Figure 4). However, intranasal challenge with Der f into
mice harboring Der f-pulsed DCs caused signiﬁcant increase
in IL-5 levels in NLF, and this activity of Der f-pulsed
DCs to produce IL-5 in vivo was signiﬁcantly suppressed
by the pretreatment with EP in vitro (Figure 4). We then
examined the inﬂuence of intranasal instillation of DCs
pretreated with EP on the appearance of IFN-γ in NLF.
As shown in Figure 4, nasal instillation of Der f into mice
harbored Der f-pulsed DCs caused signiﬁcant increase in
IFN-γ levels in NLF as compared with that from control
DCs harboring mice. In vitro treatment of Der f-pulsed DCs
with EP could not suppress the ability of cells to produce
IFN-γ in response to intranasal challenge with Der f.N L F
obtained from mice harboring Der f-pulsed DCs and treated
EPcontainedsimilarlevels(notsigniﬁcant;P>. 05)ofIFN-γ
to that from Der f-pulsed and nontreated DCs.
4. Discussion
The present study examined the inﬂuence of Der f and EP
on the function of DCs. To do this, we ﬁrstly pulsed DCs
with Der f, and then examined the inﬂuence of EP on the
production of immunomodulatory cytokines (IL-10 and IL-
12) in vitro. Second, these DCs were instilled intranasally
into na¨ ıve mice, followed by Der f exposure, and then
cytokine proﬁle and cellular changes in NLF were compared
to examine whether in vitro changes in DCs by EP could be
actually reﬂect in vivo.
DCs are the most potent APCs in priming na¨ ıve T
and B cells, and they play a key role in determining the
type of immune response [12–14]. Located in an immature
state at the site of antigen entry, DCs actively capture
and process antigens, and migrate to the draining lymph
nodes, where they present processed peptides to na¨ ıve T
cells and initiate various immune responses [19]. During
this process, DCs produce several types of cytokines, which
aﬀect the diﬀerentiation of activated T cells into Th1
or Th2 cells [12–14]. The cytokine IL-12 promotes Th1
responses and stimulates activated T cells to produce IFN-
γ, whereas it inhibits the development of IL-4-producing
Th2 cells in response to D. pteronyssimus [20]. In addition,
IL-12 markedly suppresses the IL-4-induced IgE production
from human peripheral blood leukocytes in vitro [21, 22],
suggesting that IL-12 might be capable of downregulat-
ing allergic immune responses. This hypothesis may be
supported by the observation that systemic and intranasal6 Mediators of Inﬂammation
administrationofIL-12intopreviouslysensitizedmicecould
inhibit the airway hyperreactivity against speciﬁc antigens
and metacholine as well as eosinophilia in bronchoalveolar
lavage ﬂuid [23, 24]. It is also supported by the experimental
evidence that mucosal gene transfer of IL-12 via a vaccinia
virus vector inhibited the ability of lung lymphoid cells to
produce IL-4 and IL-5, but not IFN-γ and prevented the
development of airway hyperreactivity in a mouse model
of ovalbumin-induced asthma [25]. IL-10 is ﬁrst identiﬁed
at the molecular level as a factor produced by Th2 cells,
which inhibited the production of cytokines by Th1 cells.
Although produced by Th2 cells, IL-10 inhibits many Th2
functionsrelevanttoallergicdisorders.IL-10alsoinhibitsthe
function of mast cells and eosinophils, which are associated
with allergic responses, and favorably modulates IgE to
IgG4 ratios [26]. On the other hand, IL-10 is reported to
enhance the formation of Th2 cells by downregulating IL-
12 production [27], suggesting that the role of IL-10 on the
development of allergic immune responses is controversial.
In general, however, at least at the DC level, it is likely
that DCs induce a Th1 response in high IL-12 and low
IL-10, whereas they induce a Th2 response in low IL-12
and high IL-10 [28, 29]. The present results clearly showed
that EP at 25.0ng/mL, which is similar to a therapeutic
blood level (26.9 ± 9.1ng/mL) when the patients were orally
given EP at 20mg [30], exerts both suppressive eﬀect on
IL-10 production and enhancive eﬀect on IL-12 production
from DCs. Taken together, therefore, it is reasonably to
speculate that EP inhibits the development of Th2 immune
response through the modulation of the ability of DCs
to produce immunomodulatory cytokines, especially IL-
10 and IL-12, and results in prevention of propagation of
allergic inﬂammation in nasal walls. This speculation may be
supported by the observation that administration of soluble
ovalbumin together with a monoclonal antibody against IL-
10receptortomiceledtotheenhancementofaTh1response
upon rechallenge [31].
In addition to IL-10 and IL-12, DCs are well known to be
able to produce several types of proinﬂammatory cytokines.
In the present study, we demonstrated that treatment with
EP inhibits the ability of DCs to produce cytokines such as
IL-6 and TNF-α. IL-6 is well known to be a multifunctional
cytokine that can promote the development of inﬂammatory
responses.Inadditiontoplayingessentialrolesintheprocess
of growth and diﬀerentiation of inﬂammatory cells such
as mast cells and B cells [32], this cytokine displays other
biological properties; IL-6 is the major inducer of C-reactive
protein (CRP) production in the liver, which can enhance
the ability of macrophages and neutrophils to produce
inﬂammatory mediators in local inﬂammatory lesions [33,
34]. TNF-α is also well accepted to exert several speciﬁc
immunomodulatory eﬀects [35, 36]. Furthermore, these two
cytokines and CRP are reported to be able to enhance
the activity of inﬂammatory cells to produce free radicals,
including nitric oxide and superoxide radicals, which are
the most important ﬁnal eﬀector molecules of inﬂammatory
diseases [36]. Together with these reports, the present results
may suggest that the suppressive eﬀect of EP on cytokine
production from DCs may underlie the therapeutic mode of
action of EP on allergic diseases such as allergic rhinitis and
atopic dermatitis.
Before obtaining the conclusion that the suppressive
activity of antihistamine, especially EP on Dc functions
contributes, at least in part, to the therapeutic mode of
action of the agent, it is essential for examining whether
the changes of DC functions in vitro could alter the nasal
inﬂammatory responses against speciﬁc allergic challenge
in vivo. Therefore, we then instilled nasally with Der f-
pulsed DCs treated with EP into na¨ ıve mice, and examined
the degree of allergic inﬂammatory responses in the nasal
wall against Der f challenge. The present results of in vivo
experiments were consistent with those in vitro experiments
and demonstrated that mice instilled with Der f-pulsed DCs
developed allergic inﬂammation in nasal wall as assessed
by eosinophil appearance in NLF, which concomitant with
increased production of IL-5. In contrast, mice instilled with
Der f-pulsed DCs treated with EP showed a reduction in
nasal eosinophil count and IL-5 production, but increased
IFN-γ, indicating that the in vitro functional changes noted
in Der f-pulsed DCs by the treatment with EP in vitro were
supported by these in vivo experiments. The mechanisms
by which instillation of Der f-pulsed DCs pretreated with
EP exerts the suppressive eﬀect on Th2 type cytokine, IL-
5 production in vivo are not clear at present. Our previous
work clearly showed that EP at 25ng/mL signiﬁcantly
inhibits the expression of costimulatory molecules, CD40,
CD80, and CD86, which are essential for the development of
T cell-dependent immune responses, on human peripheral
blood monocyte-derived DCs (MoDCs) in vitro [37]. It is
also reported that EP could decrease the ability of MoDCs
to both stimulate CD4+ T cells and phagocyte antigens in
vitro [37], suggesting that these inhibitory action of EP may
be responsible for the modulation of appearance of T-cell
cytokines, IL-5, and IFN-γ in NLF after Der f stimulation.
Although the present results strongly indicate that anti-
histamine, especially EP, inhibits DCs-induced Th2 skewed
immune responses and results in favorable modiﬁcation in
DCs-induced allergic immune responses in nasal walls, the
mechanism(s) by which EP could modulate DC functions
induced by speciﬁc allergen stimulation are not clear at
present. Several endogenous mediators have been reported
that modulate DC functions, including adenosine [38],
phosphodiesterase [39], prostaglandins [40], and cAMP
[41]. Among these, the inﬂuence of cAMP on cytokine
production from DCs was extensively studied and reported
that the increase in cAMP activation caused suppression of
IL-12productionandenhancedtheabilityofcellstoproduce
IL-10 [39]. It is also reported that rolipram and ciaprost,
which are pharmacological agents led to cAMP activation,
enhanced IL-10 production from human peripheral blood
monocytesinresponsetoLPSstimulation[42].Judgingfrom
these reports, the present results may be interpreted that
treatmentofDCswithEPaswellasazelastinehydrochloride,
an H1 receptor antagonist [43], inhibited cAMP activation,
which was enhanced by Der f stimulation, and results in
changesintheabilityofDCstoproduceimmunomodulatory
cytokines. There is growing evidence that cAMP response
element-binding protein (CREB), which is a 48-κDa nuclearMediators of Inﬂammation 7
transcription factor bound to cAMP response element,
modulates the ability of cells to produce proinﬂammatory
cytokines, such as TNF-α and IL-6. Inhibition of CREB
is reported to decrease IL-6 mRNA expression in vascular
smooth muscle cells and peritoneal mouse macrophages in
responsetothestimulationwiththrombin[44]anddeoxyni-
valenol[45],respectively.Itisalsoreportedthatinhibition of
CREB activation suppress the ability of macrophage cell line,
RAW264.7,toproduceTNF-αinresponsetoLPSinvitro[46,
47], suggesting that EP inhibits IL-6 and TNF-α production
from DCs induced by speciﬁc allergen stimulation through
thesuppressionof CREB activation in vitro. This speculation
may be supported by the observation that terfenadine, an H1
receptor antagonist, exerts the suppressive eﬀect on CREB
activation in mouse cholangiocytes in vitro [48]. Anyway,
further experiments are required to clarify the molecular
mechanisms by which EP could modulate DC functions,
especially cytokine production.
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